UCB's Global Corporate Website
Welcome to UCB in the United States

Oct

02

“Disease modification” in epilepsies: key questions answered

Sep

28

Employee Spotlight: Jessie Kim's Journey as a Global Regulatory Fellow

Sep

12

Disease Spotlight: Thymidine Kinase 2 Deficiency (TK2d)

Sep

11

UCB PharmD Second-Year Fellows Share Reflections and Advice

Sep

05

Announcing the 2023 UCB Family Epilepsy Scholarship Winners

Aug

28

Breaking Down the Value Chain: Patient Voices Advocating for Change

Aug

03

Employee Spotlight: David Hornbaker’s Heart for Helping Patients

Aug

01

Evolving Expectations for Dermatological Conditions

Jul

21

UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

Jun

27

Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis